Laboratory requisitions for TB-500 (5mg / 10mg) fail QA when specification fields are paraphrased. TB-500 Specification and Vial Format Review maps Repair & Recovery Research catalog data on sulanpeptide.vip.
TB-500 is a synthetic thymosin beta-4 fragment used in laboratory research on actin-binding pathway models, cell-migration assays, extracellular-matrix remodeling, and repair-signaling systems.
Research examines actin filament density by phalloidin staining and lamellipodia dynamics by live-cell imaging after peptide treatment. Corneal wound healing in rabbit models, cardiac fibroblast migration, and endothelial sprouting assays document TB-500 research applications.
Goldstein and colleagues characterized thymosin β4 as the principal actin-sequestering peptide in mammalian cells, underpinning fragment peptide research. TB-500 corresponds to thymosin β4 actin-binding domain sequences promoting actin polymerization and cell migration in corneal and cardiac wound models.
Side-by-side review of specification table, vial label, and COA prevents release errors for TB-500. Principal investigators should sign off TB-500 SKUs only after mechanism fit is documented in the study protocol.
Spec alignment: Enter exact strength notation (5mg / 10mg) in procurement systems—do not round kit counts.
Catalog identifiers for TB-500: CAS 885340-08-9, Formula: C38H68N10O14. MW 889.0 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Dose planning for TB-500 should state mass (5mg / 10mg) or molarity derived from catalog molecular weight.
Publication methods should list Cat No. and mg strength for TB-500 to support reproducibility.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for TB-500 should state whether the lot COA must meet or exceed that threshold for your Repair & Recovery Research assay type. Specification alignment for TB-500 requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Molecular identifiers for TB-500—CAS 885340-08-9, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing TB-500 should include these fields for reproducibility in Repair & Recovery Research journals. Format selection for TB-500 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for TB-500. QA sign-off should reference all four documents in the batch record.
Format selection for TB-500 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for TB-500. QA sign-off should reference all four documents in the batch record.
Molecular identifiers for TB-500—CAS 885340-08-9, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing TB-500 should include these fields for reproducibility in Repair & Recovery Research journals.
TB-500 from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.